Cargando…
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized. Here, we review the current knowledge on the therapeuti...
Autores principales: | Huang, Xing, Zhang, Xiaozhen, Li, Enliang, Zhang, Gang, Wang, Xun, Tang, Tianyu, Bai, Xueli, Liang, Tingbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325042/ https://www.ncbi.nlm.nih.gov/pubmed/32600443 http://dx.doi.org/10.1186/s13045-020-00917-y |
Ejemplares similares
-
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
por: Tang, Tianyu, et al.
Publicado: (2021) -
Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy
por: Huang, Xing, et al.
Publicado: (2020) -
Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity
por: Huang, Xing, et al.
Publicado: (2020) -
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
por: Zhang, Xiaozhen, et al.
Publicado: (2021) -
Calreticulin couples with immune checkpoints in pancreatic cancer
por: Huang, Xing, et al.
Publicado: (2020)